Objective. To describe the features and treatment of macrophage activation syndrome (MAS) in a singlecenter cohort of patients with childhood-onset systemic lupus erythematosus (SLE), and to compare childhoodonset SLE manifestations and outcomes between those with and those without MAS.
Objective. To describe the features and treatment of macrophage activation syndrome (MAS) in a singlecenter cohort of patients with childhood-onset systemic lupus erythematosus (SLE), and to compare childhoodonset SLE manifestations and outcomes between those with and those without MAS.
Methods. We included all patients with childhoodonset SLE followed up at The Hospital for Sick Children from 2002 to 2012, and identified those also diagnosed as having MAS. Demographic, clinical, and laboratory features of MAS and SLE, medication use, hospital and pediatric intensive care unit (PICU) admissions, as well as damage indices and mortality data were extracted from the Lupus database. Student's t-tests and Fisher's exact tests were used to compare continuous and categorical variables, respectively. We calculated incidence rate ratios of hospital and PICU admissions comparing patients with and those without MAS, using Poisson models. Kaplan-Meier survival analysis was used to examine the time to disease damage accrual.
Results. Of the 403 patients with childhood-onset SLE, 38 (9%) had MAS. The majority (68%) had concomitant MAS and SLE diagnoses. Fever was the most common MAS clinical feature. The frequency of renal and central nervous system disease, hospital admissions, the average daily dose of steroids, and time to disease damage were similar between those with and those without MAS.
We observed a higher mortality rate among those with MAS (5%) than those without MAS (0.2%) (P = 0.02).
Conclusion. MAS was most likely to develop concomitantly with childhood-onset SLE diagnosis. The majority of the MAS patients were successfully treated with corticosteroids with no MAS relapses. Although the numbers were small, there was a higher risk of death associated with MAS compared to SLE without MAS.
Macrophage activation syndrome (MAS) is a potentially life-threatening complication of systemic lupus erythematosus (SLE) characterized by excessive activation and proliferation of T lymphocytes and macrophages and a consequent massive production of cytokines, or "cytokine storm" (1) (2) (3) (4) . MAS is considered a secondary or acquired form of hemophagocytic lymphohistiocytosis (HLH) and is usually associated with infection, rheumatic disease, or malignancy (5) . Primary or familial HLH is caused by mutations in genes involved in the granule-dependent cytolytic secretory pathway. Despite the different inciting causes, primary and secondary HLH share similar clinical and biochemical features (5) .
MAS was initially described in association with systemic juvenile idiopathic arthritis (JIA) (6) ; however, it has been increasingly recognized as a complication of SLE (3, 5, 7) . There are only a few studies examining the clinical and laboratory features of MAS in childhoodonset SLE, and most of the available data are based on cross-sectional studies and case reports (3, (8) (9) (10) (11) (12) . As a result, the true prevalence of MAS in childhood-onset SLE is unknown. MAS is life-threatening, with mortality rates ranging from 8% to 22% in pediatric autoimmune diseases generally (11,13) and 10-22% in MAS complicating childhood-onset SLE specifically (3, 8, 14) . Yet there are limited available data on long-term outcomes, including rates of recurrence of MAS in childhood-onset SLE (3, 8, 14) . Moreover, it remains unclear whether childhood-onset SLE complicated by MAS has a distinctive disease course in terms of organ involvement and damage accrual in long-term follow-up when compared to childhood-onset SLE without MAS.
The aims of this study were to 1) describe the clinical and laboratory characteristics, outcomes, and treatment of MAS in a large childhood-onset SLE cohort from a single pediatric tertiary care center; and 2) compare clinical and laboratory SLE features and disease-associated outcomes between childhood-onset SLE patients with MAS and those without MAS.
PATIENTS AND METHODS
Study population. We included all patients diagnosed as having and followed up for childhood-onset SLE at The Hospital for Sick Children (SickKids) between January 2002 and December 2012 (n = 403). All patients met the American College of Rheumatology (ACR) and/or Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE (15, 16) . Since there are no validated or universally accepted diagnostic criteria for MAS in SLE, the diagnosis of MAS was based on the treating pediatric rheumatologist's expert opinion at the time of the initial presentation. The treating pediatric rheumatologists had 35 years (EDS) and >15 years (DML) of experience in caring for children with SLE. These diagnoses were independently reviewed by one investigator (MG), and any questionable diagnoses were brought to the attention of all authors. There were 4 cases in which the diagnosis of MAS was disputed. After individual case review, 2 were excluded as MAS cases. The final decision regarding MAS diagnosis and subsequent inclusion of the MAS patients in the study was made by agreement among all authors. Institutional Research Ethics Board (REB) approval was obtained prior to initiation of the study (REB #1000035186).
Variables. Prospectively collected demographic, clinical, and laboratory data on SLE and MAS features were extracted from the SickKids Lupus database and supplemented by data from hospital medical records. The diagnoses of MAS and childhood-onset SLE were considered "concomitant" if MAS was diagnosed within 7 days of childhood-onset SLE.
Demographic features included age at diagnosis of childhood-onset SLE, age at diagnosis of MAS, and sex. The following clinical MAS features (3, 17) were extracted: fever, hepatosplenomegaly, lymphadenopathy, clinical bleeding episodes (hemorrhages), and central nervous system (CNS) involvement. CNS involvement secondary to MAS was defined as any evidence of altered level of consciousness or seizures at the time of MAS presentation, excluding those associated with infections, drugs, or metabolic causes. Since MAS with CNS involvement may overlap with the clinical spectrum of neuropsychiatric SLE (NPSLE) (18) , the definition of CNS disease secondary to MAS was based on a multidisciplinary team approach including pediatric neurologists, neuroradiologists, oncologists, and rheumatologists.
Laboratory MAS features extracted included platelet count, hemoglobin, white blood cell differential count, alanine aminotransferase, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), ferritin, fibrinogen, triglyceride level, D-dimers, partial thromboplastin time, serum sodium level, C-reactive protein level, and erythrocyte sedimentation rate. Additional laboratory features such as natural killer (NK) cell cytotoxic activity, soluble interleukin-2 receptor (sIL-2R) levels, bone marrow aspirate/biopsy findings, and evaluations for infection were also included when available. We also reviewed the results of Sanger sequencing of exons 2 and 3 in the perforin gene (PRF1) (19) (21) . The definition of CNS disease secondary to SLE was based on ACR 1999 nomenclature and case definitions for NPSLE syndromes (18) . In order to assess SLE disease severity and long-term SLE outcomes in patients with MAS and patients without MAS, the following variables were recorded: immunosuppressive drug use, average daily dose of corticosteroids, and number of pediatric intensive care unit (PICU) admissions during follow-up. Hospital admissions with a length of stay of ≥72 hours were considered clinically relevant in order to assess and compare lupus disease severity between patients with MAS and patients without MAS over the follow-up period. However, hospital admissions that were entirely for medical procedures (e.g., for kidney biopsy) were excluded since they were not considered an accurate indicator of disease severity. All deaths during follow-up at SickKids were documented in both groups. The SLICC/ACR Damage Index (SDI), previously validated in childhood-onset SLE, was used to assess damage 6 months after diagnosis of childhood-onset SLE and at each subsequent visit in both groups (22, 23) . All variables were collected until the last lupus clinic visit at SickKids.
Statistical analysis. Demographic data, clinical features, and laboratory features were analyzed using descriptive statistics. Continuous and categorical variables were compared between patients with and those without MAS, using Student's t-test and Fisher's exact test, respectively. Incidence rate ratios (IRRs) were calculated using Poisson models to compare the rates of hospital and PICU admissions between those with and those without MAS. Kaplan-Meier survival analyses were used to examine the rate of disease damage accrual over time in both cohorts. P values less than 0.05 were considered statistically significant, and a Bonferroni correction for multiple testing was used when testing multiple independent associations. All statistical analyses were performed using Stata release 14 (StataCorp).
RESULTS
Demographic data. Of the 403 patients in our childhood-onset SLE cohort who were diagnosed and followed up at SickKids Hospital, 38 (9%) had MAS. The majority of the MAS patients were female (79%), the mean AE SD age at SLE diagnosis was 13.7 AE 2.8 years, and the mean AE SD length of follow-up was 3.5 AE 1.6 years. We did not observe a difference in age at SLE diagnosis or in the duration of follow-up between the patients with MAS and the patients without MAS (Table 1 and Figure 1) . MAS was diagnosed concomitantly with childhood-onset SLE in the majority of the patients (68%), and 18% were diagnosed with MAS within 180 days of childhood-onset SLE diagnosis. Only 11% developed MAS >180 days after diagnosis of childhood-onset SLE. In 1 patient, the diagnosis of MAS secondary to Kikuchi-Fujimoto disease preceded the diagnosis of childhood-onset SLE by 3 years. There was no statistically significant change in annual incidence of MAS over the study period in our childhood-onset SLE cohort (data not shown).
Clinical and laboratory MAS features at presentation and initial treatment in the MAS cohort. Clinical and laboratory features of MAS. All MAS patients had fever at presentation. The second most common manifestation was generalized lymphadenopathy (24%) Figure 1 . Age at diagnosis of childhood-onset systemic lupus erythematosus (cSLE) in patients with macrophage activation syndrome (MAS; n = 38) and patients without MAS (n = 365). The x-axis shows the age in years at diagnosis of childhood-onset SLE, and the y-axis shows the percentage of patients with MAS and those without MAS diagnosed in each age category.
followed by CNS involvement secondary to MAS (18%) ( Table 2 ). Attribution of CNS manifestations to either MAS or childhood-onset SLE was difficult in some cases, but upon review, attribution was agreed upon by all authors. An example of MAS CNS involvement included focal seizures with residual hemiparesis and subsequent coma with biochemical evidence of MAS. Another patient had onset of CNS lupus manifestations, including visual hallucinations and cognitive slowing, 1 week after treatment for MAS. Due to the nature and timing of her symptoms, and since other MAS manifestations such as pancytopenia and diffuse lymphadenopathy improved, her CNS manifestations were attributed to childhoodonset SLE. /liter, 34 (89%); for platelet count ≤150 cells 9 10 9 /liter, 23 (61%); for aspartate aminotransferase (AST) >40 units/liter, 37 (97%); for lactate dehydrogenase (LDH) >567 IU/liter, 35 (97%); for fibrinogen ≤1.5 gm/liter, 3 (9%); for ferritin >500 lg/liter, 32 (89%); and for triglycerides >2 mmoles/liter (or >178 mg/dl), 25 (71%). † † Tacrolimus (for 2 patients) or cyclosporine (for 11 patients).
All MAS patients had ferritin levels above the laboratory reference range. Elevated LDH and AST levels were each present in 97% of the patients (Table 2) . NK cell cytotoxic activity was found to be normal in all 3 patients tested, and sIL-2R levels were elevated in all 4 patients tested (median concentration 3,239 units/ml [range 1,047-7,012]; normal range 460-1,580 units/ml). Seven patients had PRF1 sequencing, and 6 had exome sequencing of HLH-associated genes. The majority (11 of 13) did not carry variants associated with HLH, with the remainder of those tested being heterozygous carriers of variants of uncertain significance in LYST or RAB27A (minor allele frequencies of 0.001-0.015 depending on the ancestral population).
There was evidence of hemophagocytosis in 32% of the patients who underwent bone marrow aspirate/ biopsy ( Table 2) . A minority of patients (16%) had documented concomitant infections at the time of MAS presentation (1 group A streptococcal bacteremia, 1 herpes simplex virus type 1 cutaneous infection, 1 acute EpsteinBarr virus infection, 1 Escherichia coli urinary tract infection [UTI], 1 Candida UTI, and 1 disseminated tuberculosis infection), and 1 patient received the meningococcal vaccination 2 weeks prior to MAS diagnosis. All patients with childhood-onset SLE clinically diagnosed as having MAS met the preliminary diagnostic criteria for MAS proposed by Parodi et al (3) ( Table 2) . MAS treatment. All MAS patients were treated with corticosteroids ( Table 2 ). The majority (68%) received intravenous (IV) high-dose methylprednisolone followed by either oral prednisone or lower-dose IV methylprednisolone. Twenty-two patients (58%) received IV immunoglobulin. One-third of the patients received an oral calcineurin inhibitor, and 13% received etoposide. Two patients died during the acute phase of MAS. Both required anakinra and plasmapheresis, while one also received alemtuzumab and intrathecal methotrexate due to severe, refractory CNS disease secondary to MAS (Table 2) .
MAS outcome. The mean AE SD duration of follow-up from the time of SLE diagnosis to the last visit was 3.5 AE 1.6 years for MAS patients. All patients required hospital admission at MAS diagnosis, and 21% also required PICU admission. Of the 2 MAS patients who died during the acute episode, one had CNS disease and disseminated tuberculosis, and the other had CNS involvement (brain biopsy showing CD163+ macrophage, erythrophagocyte, and lymphophagocyte infiltrate).
Three of the 5 patients with seizures had no further seizure recurrence after the MAS episode resolved. The 2 patients who initially presented with isolated altered levels of consciousness had normal brain magnetic resonance imaging scans at presentation and completely recovered without further CNS involvement. None of the MAS patients experienced a MAS recurrence during follow-up at SickKids.
Comparison of SLE clinical and laboratory features and treatment between patients with MAS and those without MAS. The mean AE SD duration of followup among patients with childhood-onset SLE without MAS was 4 AE 2.4 years. Over the follow-up period, a higher proportion of those with MAS had lymphopenia, thrombocytopenia, and anti-double-stranded DNA (antidsDNA) antibodies compared to the group without MAS (P < 0.01) ( Table 1 ). The average daily dose of prednisone or prednisone equivalent over the course of follow-up (including use for MAS treatment) was similar between the cohort with MAS and the cohort without MAS (mean AE SD 18.3 AE 7.3 mg/day versus 18.6 AE 18.7 mg/day, respectively; P = 0.94), as was the proportion of patients who received immunosuppressive agents during the follow-up period (Table 3 ). There was a trend toward more frequent azathioprine use in the group without MAS than in the group with MAS, but this was not statistically significant after Bonferroni correction for multiple comparisons (Table 3) .
SLE outcomes in the patients with MAS and those without MAS. There were no differences in the rate of hospital or PICU admissions per year between the patients with MAS and those without MAS during the follow-up period (IRR 1.11 [95% confidence interval 0.83-1.48] for hospital admissions and IRR 1.60 [95% confidence interval 0.74-3.18] for PICU admissions in the group with MAS compared to the group without MAS). (9) * Values are the number (%). All patients with macrophage activation syndrome (MAS) received either corticosteroids or other immunosuppressive drugs during follow-up. Of the 365 patients without MAS, 68 (18%) did not receive any immunosuppressive agents (including corticosteroids) during follow-up. IV = intravenous; IVIG = IV immunoglobulin. † P = 0.01 (P < 0.007 following Bonferroni correction for multiple treatments) versus patients with MAS. ‡ Tacrolimus or cyclosporine used to treat childhood-onset systemic lupus erythematosus (SLE) only (excluding use for treatment of MAS). § Excluding use for treatment of MAS only.
BORGIA ET AL
There was a trend toward a higher proportion of patients with PICU admissions within the first year after diagnosis of childhood-onset SLE in the MAS group (all related to acute MAS presentation) compared to patients without MAS; however, the difference was not statistically significant (23% of the patients with MAS versus 10% of the patients without MAS [P = 0.05]). There was no difference between groups in the proportion of patients who sustained damage (SDI ≥1) during follow-up (P = 0.3) (Figure 2 ). Cataracts were the most common manifestation of damage at the last clinic visit in both groups, followed by avascular necrosis, cognitive impairment, and osteoporosis with fracture or vertebral collapse. Although numbers were small, there was a higher mortality rate in the group with MAS (2 patients [5%]) than in the group without MAS (1 patient [0.3%]) (P = 0.02). Both deaths in the MAS cohort occurred in the acute period of MAS presentation, and the death of the patient without MAS occurred 9 years after SLE diagnosis due to a malignancy (Table 4) .
DISCUSSION
MAS is an increasingly recognized, life-threatening complication of SLE. However, the natural history of MAS among patients with childhood-onset SLE is unknown. In our population of >400 patients with childhood-onset SLE, those who developed MAS were most likely to be diagnosed as having MAS concomitantly with childhoodonset SLE and did not experience relapses of MAS during the follow-up period. We observed higher rates of lymphopenia, thrombocytopenia, and anti-dsDNA antibody positivity among those with MAS compared to those without MAS. There were no differences in the frequency of other SLE clinical features or in rates of disease damage at last follow-up. Although our mortality numbers were small, we observed a higher mortality rate among those with MAS compared to those without MAS, where deaths in the MAS group occurred in the acute period of MAS disease.
Although the first case of MAS secondary to SLE was reported in 1984, it was not until a 1991 report of 6 cases that MAS was recognized as a complication of SLE (24, 25) . A 2014 systematic review found 133 cases of MAS secondary to adult SLE reported in the literature, making it the most common cause of MAS in adults with rheumatic diseases (5). There has not been a similar review of MAS in pediatric rheumatology; however, most large series report that MAS is more common in patients with systemic JIA than in those with childhood-onset SLE (8, 26) . The prevalence of MAS in our childhood-onset SLE cohort of 9% is approximately double the prevalence (4%) reported in reviews and large series examining MAS prevalence in adult SLE (5, 26, 27) . This difference in prevalence may reflect diagnostic bias or a true difference in the risk of MAS between childhood-onset SLE and adult SLE.
Findings in the initial case series suggested that MAS usually occurred at the time of diagnosis of adult SLE (24) ; however, subsequent studies of adult SLE found that MAS frequently occurred at the time of disease flare as well (28, 29) . We found that MAS was most likely to develop concomitantly or within 1 month of SLE diagnosis, which is consistent with the findings of other childhood-onset SLE series that examined the timing of MAS relative to SLE diagnosis (3, 14) . Of note, 1 patient in our cohort developed MAS 3 years prior to childhoodonset SLE diagnosis, and 1 patient who died had SLE Fever was the only clinical MAS feature present in all MAS patients in our cohort, as observed in prior studies of both adult SLE patients and childhood-onset SLE patients (3, 7, 9) . Other clinical features were much less frequently found in our MAS cohort, with generalized lymphadenopathy found in 24% and CNS dysfunction and hepatomegaly each found in 18% of the patients. In contrast, others have reported higher frequencies of lymphadenopathy, hepatomegaly, and CNS dysfunction, in the range of 40-50% (3, 7, 9) . The most common laboratory features in our MAS cohort were elevated AST, LDH, and ferritin levels as well as leukopenia, with rates similar to those in previous studies (3, 7) .
We observed that only one-third of the MAS patients who underwent a bone marrow aspirate/biopsy had evidence of hemophagocytosis. This rate is lower than rates in other series of adult patients; however, many of those adult series required the presence of hemophagocytosis on bone marrow aspirate/biopsy or lymph node/liver biopsy to make the diagnosis of MAS (1, 27, 30) . We also compared the MAS clinical and laboratory features between those with and those without hemophagocytosis among those who underwent bone marrow aspiration/ biopsy (n = 25), and found no significant differences between the groups (data not shown). We suggest that the absence of increased hemophagocytosis on bone marrow examination should not delay the diagnosis of MAS and initiation of therapy. However, bone marrow examination may be required to rule out other processes such as malignancy or infections (e.g., leishmaniasis).
Although MAS has been reported to recur in patients with systemic JIA, recurrence rates are rarely reported in childhood-onset SLE. None of the patients in our cohort experienced a recurrence of MAS during a mean follow-up of 3.5 years. Similarly, other studies of childhood-onset SLE did not observe recurrence of MAS (follow-up times not specified) (1, 14) . In contrast, 2 studies of adult SLE have shown MAS recurrence in 3 of 12 patients after a mean of 7.1 years of follow-up, and in 4 of 14 adult SLE patients (follow-up time not specified) (1, 30) . Therefore, although the numbers are small, recurrence of MAS has not been reported in childhood-onset SLE but may occur in up to 25% of cases in adult SLE (1, 14, 30, 31) .
We observed a mortality rate of 5% among those with MAS, which is lower than the mortality rate reported in most MAS studies in childhood-onset SLE and adult SLE (up to 22%) (1, 3, 7, 8, 14, 27, 29) . In our cohort, 7 MAS patients had CNS manifestations attributed to MAS. Of those, 2 (29%) died with severe CNS involvement and multiple organ failure. (One patient also had concomitant disseminated tuberculosis infection.) Consistent with our findings, a previous study of 19 patients with childhoodonset SLE with MAS suggested that CNS involvement was also associated with a higher mortality rate with multiple organ failure or sepsis frequently as the terminal event (8).
We did not find any significant differences in SLE manifestations between the patients with MAS and those without MAS at presentation or within the first year after diagnosis of SLE (data not shown). An earlier study of 38 patients with childhood-onset SLE and MAS found that these patients had a higher frequency of major organ involvement (lupus nephritis and CNS involvement), hematologic involvement, arthritis, serositis, and oral/ nasal ulcers at the time of SLE diagnosis than patients without MAS (n = 387) (3). These differences between studies may reflect differences in the childhood-onset SLE cohorts or applied MAS definitions. However, both our study and the study by Parodi et al (3) showed higher rates of hematologic involvement in the group with MAS than in the group without MAS, which may be the result of cytopenias secondary to MAS itself.
Following the acute illness that was associated with 2 deaths secondary to MAS, we did not find any significant differences in the number of deaths or damage accrual between the cohorts, including overall SDI or any specific damage feature within the score. MAS is a lifethreatening complication of childhood-onset SLE and it should be considered an important cause of mortality in childhood-onset SLE. However, if the initial presentation did not result in death, the long-term outcome seemed to be comparable to that for patients without MAS, and treatment-related damage was not increased in our MAS cohort. We acknowledge that our study has some limitations. There is currently a lack of validated criteria for MAS in SLE. Hence, we identified patients with MAS based on pediatric rheumatologist expert opinion. However, the diagnosis of MAS was validated by consensus of all the contributing authors. It is therefore possible, but unlikely, that we missed cases. Although all clinical and laboratory data were prospectively collected and entered into our database, we retrospectively reviewed the completeness of data collection with respect to MAS features. Hence, some laboratory data were missing at the time of MAS diagnosis. Although our follow-up extended a mean of 3.5 years, we were unable to obtain data on most patients beyond 18 years of age, into adulthood.
MAS is a potentially fatal complication of pediatric rheumatic diseases. We observed that, unlike in adult SLE, in our childhood-onset SLE cohort MAS was most frequently seen at the time of diagnosis of SLE and did not recur during follow-up. We have demonstrated for the first time that the SLE disease course and outcome did not differ between patients with childhoodonset SLE complicated with MAS and those without MAS. Although a bone marrow examination is frequently warranted in the setting of MAS presentation, in particular to rule out other disease processes, absence of significant hemophagocytosis on bone marrow examination is frequent. The clinical presentation of persistent fever, leukopenia (usually associated with a decrease in a second lineage), and elevated ferritin levels and liver enzymes should raise the suspicion of MAS in patients with childhood-onset SLE.
